Scientific Sessions 2024  /  Featured Science: Getting Closer to the Summit: New HFpEF Treatments  /  The Arc of Heart Failure
Logo

American Heart Association

  131
  0

Final ID:

The Arc of Heart Failure

  • Pfeffer, Marc  ( BRIGHAM and WOMENS HOSPITAL , Boston , Massachusetts , United States )
    • Author Disclosures:
    Marc Pfeffer: DO have relevant financial relationships ; Consultant:Alexion, Alnylam, Apnimed, AstraZeneca, Boehringer Ingelheim and Eli Lilly Alliance, DalCor, Intellia, Novartis, and Novo Nordisk. :Active (exists now) ; Individual Stocks/Stock Options:Dal-Cor:Active (exists now) ; Researcher:Lexicon, Novartis:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Getting Closer to the Summit: New HFpEF Treatments

Sunday, 11/17/2024 , 08:00AM - 09:15AM

Featured Science

More abstracts on this topic:
Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights from the SUMMIT trial

Borlaug Barry

Bisecting the Future of HFpEF Therapy: Medical and Procedural Therapy

Redfield Margaret, Reza Nosheen

More abstracts from these authors:
Kidney and cardiac biomarkers and risk of adverse kidney outcomes in patients with type 2 diabetes and kidney disease, cardiovascular disease, or both

Mc Causland Finnian, Vaduganathan Muthiah, Pfeffer Marc, Claggett Brian, Solomon Scott, Chaturvedi Nishi, De Zeeuw Dick, Malachias Marcus, Mcgrath Martina, Mcmurray John, Neuen Brendon

Discussant: ANSWER-HF

Pfeffer Marc, Solomon Scott, Lopes Renato

You have to be authorized to contact abstract author. Please, Login
Not Available